Bispecific Antibody Cadonilimab Shows Survival Edge Over PD-1 Drugs in Gastric Cancer
A network meta-analysis of eight Phase III trials involving 7,127 patients suggests that the PD-1/CTLA-4 bispecific antibody cadonilimab plus chemotherapy ...
A network meta-analysis of eight Phase III trials involving 7,127 patients suggests that the PD-1/CTLA-4 bispecific antibody cadonilimab plus chemotherapy ...
A new study shows that the lipid receptor OLR1 drives gastric cancer progression by activating NF-κB signaling and polarizing macrophages ...
A Japanese study found that immune-related adverse events during checkpoint inhibitor therapy for advanced gastric cancer were independently linked to ...
A new Bayesian modelling study shows that although childhood Helicobacter pylori infections in China have fallen sharply since the 1980s, ...
Researchers in China have developed a Transformer-CNN deep learning framework that segments and grades gastric intestinal metaplasia in whole slide ...
A 12-year Japanese database study of 16,573 patients shows first-line nivolumab plus chemotherapy rapidly displaced cisplatin-based regimens in HER2-negative advanced ...
Gastric cancer may be exploiting a little-known metabolic molecule to disable the immune system, according to research from Keio University ...
In a groundbreaking development that could revolutionize the therapeutic landscape of gastric cancer, researchers have unveiled the pivotal role of ...
© 2025 Scienmag - Science Magazine
© 2025 Scienmag - Science Magazine